NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

NCT06577519

RecruitingPhase 3

Sponsor: Jiangsu vcare pharmaceutical technology co., LTD

Conditions: Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

Interventions: Vicagrel, Clopidogrel

Countries: China

This is a multi-center, randomized, double-blind, double-dummy, parallel-controled, phase III trial, aiming to evaluate the effectiveness and safety of long-term continuous administration of Vicagrel capsules in ACS patients undergoing PCI.

Eligibility overview

Sex: ALL

Age: 18 Years to 80 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Patients between 18 and 80 years old, with no gender restrictions.
* Patients diagnosed with ACS and scheduled for PCI, including STEMI and NSTE-ACS (UA/NSTEMI).
* Voluntarily sign the ICF and be able to follow the visit arrangements specified in the protocol during the trial period.

Exclusion Criteria:

* Expected survival time\<12 months;
* Severe liver dysfunction (non heart disease induced ALT or AST\>3x ULN) and cirrhosis;
* Pregnant or lactating women, or participants and their partners who plan to become pregnant during the trial period;
* The researchers determined that other reasons were not suitable for participants in this experiment.

Locations (1)

Shenyang, Liaoning, China